Mandate

Vinge has advised Xpray Pharma in connection with share issue

November 08, 2021 Capital Markets and Public M&A

Vinge has advised Xspray Pharma, a pharmaceutical company with several product candidates in clinical development listed on Nasdaq Stockholm, in connection with a share issue whereby the company raises proceeds of approximately SEK 100 million.

Vinge’s team consisted of Dain Hård Nevonen, Linnéa Sellström and Joel Magnusson.

Related

Vinge has advised Skeptiva AB in connection with its financing round

Skeptiva is developing the next generation of cybersecurity defenses against fraud. The company has developed an AI application that detects attacks and alerts users in real time.
March 11, 2026

Vinge has advised Main Capital in connection with the acquisition of Good Solutions Sweden AB

Good Solutions Sweden AB (”Good Solutions”) provides software that helps factories identify and reduce production losses. The software converts data from machines and operators into insights that can be used to streamline production and increase profitability.
March 11, 2026

Vinge represents Studsvik AB (publ) in the acquisition of Kärnfull Next AB

Vinge has represented Studsvik AB (publ) in connection with the acquisition of Kärnfull Next AB, a company developing methods for building small modular nuclear reactors.
March 10, 2026